Recently, the combination of tumor-targeting antibodies with SIRPα-CD47 blockade has provided promising clinical results, suggesting that increased phagocytosis of cancer cells is clinically relevant for treatment of hematologic cancers [1]. This evidence concerns the gene CD47 and hematopoietic and lymphoid cell neoplasm.